GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hard to Treat Diseases Inc (OTCPK:HTDS) » Definitions » Shiller PE Ratio

HTDS (Hard to Treat Diseases) Shiller PE Ratio : (As of Sep. 21, 2024)


View and export this data going back to . Start your Free Trial

What is Hard to Treat Diseases Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Hard to Treat Diseases does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Hard to Treat Diseases Shiller PE Ratio Historical Data

The historical data trend for Hard to Treat Diseases's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hard to Treat Diseases Shiller PE Ratio Chart

Hard to Treat Diseases Annual Data
Trend
Shiller PE Ratio

Hard to Treat Diseases Quarterly Data
Shiller PE Ratio

Competitive Comparison of Hard to Treat Diseases's Shiller PE Ratio

For the Biotechnology subindustry, Hard to Treat Diseases's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hard to Treat Diseases's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hard to Treat Diseases's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Hard to Treat Diseases's Shiller PE Ratio falls into.



Hard to Treat Diseases Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Hard to Treat Diseases does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.


Hard to Treat Diseases  (OTCPK:HTDS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Hard to Treat Diseases Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Hard to Treat Diseases's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hard to Treat Diseases Business Description

Traded in Other Exchanges
N/A
Address
2655 Ulmerton Road, No. 338, Clearwater, FL, USA, 33762
Hard to Treat Diseases Inc operates medical and cosmetics company in Europe, and Mainland China. It is s also in the process of developing its own stem cell bank.

Hard to Treat Diseases Headlines

No Headlines